Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Process of Preparing mRNA-Loaded Lipid Nanoparticles

a technology of lipid nanoparticles and lipid nanoparticles, which is applied in the direction of transferases, peptide/protein ingredients, drug compositions, etc., can solve the problems of time-consuming, unpredictable, and expensive existing approaches, and achieve the effect of efficient in vivo delivery and potent protein expression

Inactive Publication Date: 2018-06-07
TRANSLATE BIO INC
View PDF8 Cites 54 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides an improved process for making mRNA-loaded lipid nanoparticles. This process results in more potent and effective protein expression in vivo, which is important for treating various diseases. The process is scalable and efficient, using different pump systems. The resulting particles are also smaller and more uniform in size. Overall, this invention offers better efficacy, lower costs, and more patient-friendly dosing options for mRNA therapy.

Problems solved by technology

However, these existing approaches are costly, time consuming and unpredictable.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process of Preparing mRNA-Loaded Lipid Nanoparticles
  • Process of Preparing mRNA-Loaded Lipid Nanoparticles
  • Process of Preparing mRNA-Loaded Lipid Nanoparticles

Examples

Experimental program
Comparison scheme
Effect test

example 1

oparticle Formulation Process A

[0200]This example illustrates an exemplary lipid nanoparticle formulation process for encapsulating mRNA. As used herein, Process A refers to a conventional method of encapsulating mRNA by mixing mRNA with a mixture of lipids, without first pre-forming the lipids into lipid nanoparticles. As compared to Process B described below, Process A does not involve pre-formation of lipid nanoparticles.

[0201]An exemplary formulation Process A is shown in FIG. 1. In this process, in some embodiments, the ethanol lipid solution and the aqueous buffered solution of mRNA were prepared separately. A solution of mixture of lipids (cationic lipid, helper lipids, zwitterionic lipids, PEG lipids etc.) was prepared by dissolving lipids in ethanol. The mRNA solution was prepared by dissolving the mRNA in citrate buffer, resulting in mRNA at a concentration of 0.0833 mg / ml in citrate buffer with a pH of 4.5. As shown in FIG. 1, the mixtures were then both heated to 65° C. ...

example 2

oparticle Formulation Process B with Pre-Formed Lipid Nanoparticles

[0202]This example illustrates an exemplary Process B for encapsulating mRNA. As used herein, Process B refers to a process of encapsulating messenger RNA (mRNA) by mixing pre-formed lipid nanoparticles with mRNA. A range of different conditions, such as varying temperatures (i.e., heating or not heating the mixture), buffers, and concentrations, may be employed in Process B. The exemplary conditions described in this and other examples are for illustration purposes only.

[0203]An exemplary formulation Process B is shown in FIG. 2. In this process, in some embodiments, lipids dissolved in ethanol and citrate buffer were mixed using a pump system. The instantaneous mixing of the two streams resulted in the formation of empty lipid nanoparticles, which was a self-assembly process. The resultant formulation mixture was empty lipid nanoparticles in citrate buffer containing alcohol. The formulation was then subjected to a...

example 5

ASS1 Expression in 293T Cells

[0217]This example illustrates that the lipid nanoparticles prepared by Process B resulted in unexpectedly high protein expression in transfected cells.

[0218]FIG. 5 depicts exemplary human ASS1 protein expression in 293T cells 16 hours post-transfection with either naked hASS1 mRNA (with lipofectamine) or hASS1 mRNA-encapsulated lipid nanoparticles (without lipofectamine) produced by Process A or Process B.

[0219]In this example, 293T cells were transfected with ASS1 mRNA lipid nanoparticle formulations prepared by Process A or by Process B. Either 1 μg of ASS1 mRNA was transfected using lipofectamine or 10 μg of ASS1 mRNA encapsulated in lipid nanoparticle formulations were transfected per 106 cells for 24 hours. ASS1 protein expression was determined by ELISA.

[0220]As shown in FIG. 5, the lipid nanoparticle formulation prepared by Process B lead to much higher levels of ASS1 protein expression than the formulation prepared by Process A. The levels of AS...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA.

Description

RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application Ser. No. 62 / 420,413, filed Nov. 10, 2016 and U.S. Provisional Application Ser. No. 62 / 580,155, filed Nov. 1, 2017, the disclosures of which are hereby incorporated by reference.SEQUENCE LISTING[0002]The present specification makes reference to a Sequence Listing (submitted electronically as a .txt file named “MRT-1246US_SL” on Nov. 10, 2017). The .txt file was generated Nov. 10, 2017 and is 17,482 bytes in size. The entire contents of the Sequence Listing are herein incorporated by reference.BACKGROUND[0003]Messenger RNA therapy (MRT) is becoming an increasingly important approach for the treatment of a variety of diseases. MRT involves administration of messenger RNA (mRNA) to a patient in need of the therapy for production of the protein encoded by the mRNA within the patient's body. Lipid nanoparticles are commonly used to encapsulate mRNA for efficient in vivo delivery of mRNA.[0004]To imp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/51A61K38/53A61K38/44A61K38/18A61K38/17A61K38/45
CPCA61K9/5192A61K9/5123A61K38/45C12Y201/03003A61K38/53C12Y603/04005A61K38/177A61K38/44C12Y114/16001A61K38/1816A61K47/22A61K47/28A61K9/1272C12N15/88A61P43/00
Inventor KARVE, SHRIRANGDEROSA, FRANKBHAVSAR, ZARNAHEARTLEIN, MICHAEL
Owner TRANSLATE BIO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com